Diffuse large B cell lymphoma: how can we cure more patients in 2012?
Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.